Merck’s PIFELTRO™ and DELSTRIGO™ receive FDA approval for use in adults with HIV-1
Merck announced the FDA approved sNDAs for PIFELTRO™ and DELSTRIGO™ that expand their indications to include adult patients with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. September 20, 2019